EIF4E and B-cell chronic lymphocytic leukemia: We found that the non-CLL or healthy B cells were inhibited by the HDAC2A and eIF4E inhibitors in a dose-dependent manner, whereas the CLL cells displayed reduced sensitivity (Figure 7).